en.Wedoany.com Reported - Japanese medical technology company Olympus disclosed on June 2 that it had completed the acquisition of Israeli medical device company BioProtect Ltd. on June 1. The transaction, previously announced on May 26, was valued at $270 million, making BioProtect a wholly-owned subsidiary of Olympus. Olympus has further extended its urology, oncology, and endoscopy-related treatment portfolio into the field of prostate cancer radiotherapy protection devices.
BioProtect, headquartered in Netanya, Israel, was founded in 2004 and is primarily engaged in the research, development, and manufacturing of biodegradable rectal spacer balloons. Its core product, the BioProtect Balloon Spacer, is used in prostate cancer radiotherapy scenarios. It creates a stable spacer between the prostate and critical tissues such as the rectum, reducing radiation exposure to healthy tissues during treatment; the implant naturally degrades after treatment concludes. In its acquisition announcement, Olympus positioned BioProtect as an "innovative spacer solutions" company and clarified that the transaction serves its expansion in urology, gastroenterology, and oncology-related adjacent therapeutic areas. For a medical technology company long known for its digestive endoscopy, diagnostic, and minimally invasive treatment devices, this acquisition is not merely about adding a single consumable product. Instead, it extends the endoscopy-related care pathway into prostate cancer radiotherapy auxiliary devices, urological treatment scenarios, and oncology treatment support systems. Since its commercial introduction in 2023, the BioProtect product has been used in over 11,000 procedures globally. Olympus also noted that prostate cancer is the second most common cancer in men, with approximately 1.5 million new cases diagnosed worldwide each year, and the rectal spacer market is expected to grow over the next decade. As radiotherapy technology advances toward higher precision, higher single-fraction doses, and shorter treatment courses, reducing the risk to adjacent tissues like the rectum while improving tumor control is becoming a key direction for innovation in prostate cancer radiotherapy devices.
Following the completion of the transaction, Olympus holds all voting rights of BioProtect. Multiple institutional investors from BioProtect's original shareholder structure have exited, and the related business will be integrated into the Olympus system.
From an industry perspective, urological oncology devices are shifting from competition centered on standalone imaging, surgical, and radiotherapy equipment to competition based on the combined capabilities of a complete treatment pathway. Prostate cancer patients may involve multiple stages after diagnosis, including imaging examinations, needle biopsies, radiotherapy, surgery, follow-up monitoring, and quality of life management. If a device company only covers single-point equipment, it is difficult to form sustained service capabilities within hospitals. Olympus's strengths were originally concentrated in endoscopy and minimally invasive diagnosis and treatment. BioProtect's biodegradable spacer balloon addresses the tissue protection aspect during prostate cancer radiotherapy. The combination of the two can help Olympus establish a more direct product connection among urology, radiation oncology, and oncology treatment support devices. For medical institutions, the rectal spacer does not replace the radiotherapy equipment itself, but it affects treatment planning, dose distribution, safety margins, and patients' long-term quality of life. For medical device companies, the commercialization of such products requires clinical education, physician training, channel coverage, payment pathways, and multi-regional regulatory compliance. After Olympus takes over BioProtect, the core variables will focus on global channel amplification, product market access, physician training on usage, and synergy efficiency with existing urology and endoscopy businesses.
In its closing announcement, Olympus stated that the financial impact of the acquisition is still under evaluation, and further disclosures will be made if necessary. As global oncology treatment continues to move toward precision, minimally invasive approaches, and patient quality of life management, prostate cancer radiotherapy protection, biodegradable implantable devices, and urological oncology equipment will become important directions for medical technology companies to strengthen their treatment chains.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
